{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:17:19Z","timestamp":1793891839514,"version":"4.8.0"},"reference-count":61,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Immune checkpoint inhibitors (ICIs) show efficacy in treatment of several solid tumors, but microsatellite-stable rectal cancer is largely resistant. Radiotherapy may enhance tumor immunogenicity and thus may make the combination of radiotherapy and ICIs a promising strategy to treat rectal cancer. While anti\u2013programmed cell death protein 1 antibodies in neoadjuvant regimens have been linked to higher complete response rates, the added benefit of including a cytotoxic T-lymphocyte\u2013associated protein 4 (CTLA-4) inhibitor remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the safety and feasibility of combining ipilimumab and nivolumab with neoadjuvant chemoradiotherapy (CRT) for rectal cancer.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n The CHINOREC trial was a prospective, randomized, open-label, multicenter phase 2 clinical trial conducted from June 2, 2020, to March 15, 2024, across multiple academic and tertiary medical centers in Austria. Analysis was based on intention to treat.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n \n Neoadjuvant CRT consisted of 50 Gy in 2-Gy fractions with concurrent capecitabine (1650 mg\/m\n 2<\/jats:sup>\n \/d). The experimental arm received additional intravenous ipilimumab (1 mg\/kg on day 7) and nivolumab (3 mg\/kg every 2 weeks starting on day 14) (CRT plus ipilimumab and nivolumab group). Surgical resection was performed 10 to 12 weeks after CRT.\n <\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n The primary outcome was the safety and feasibility of combining CRT with sequential ipilimumab and nivolumab, assessed by surgical complications and reoperation rates. Secondary outcomes included clinical and pathological response rates.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Of the 145 patients assessed, 80 were randomized to receive either CRT alone (CRT group) (n\u2009=\u200930) or to the CRT plus ipilimumab and nivolumab group (n\u2009=\u200950) (49 male [61%]; median age, 60 [range, 36-83] years). Differences in surgical complication rates were not statistically significant between the CRT and CRT plus ipilimumab and nivolumab groups (any grade, 20 of 26 patients [77%] vs 33 of 43 [77%];\n P<\/jats:italic>\n \u2009&amp;gt;\u2009.99), as were reoperation rates (2 of 26 [8%] vs 3 of 43 [7%];\n P<\/jats:italic>\n \u2009&amp;gt; .99). Major pathological response (10 of 26 [38%] vs 16 of 43 [37%];\n P<\/jats:italic>\n \u2009&amp;gt;\u2009.99) and complete response (9 of 30 [30%] vs 11 of 50 [22%];\n P<\/jats:italic>\n \u2009=\u2009.44) rates were overall high in both groups.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial of patients with rectal cancer, integrating ipilimumab and nivolumab into neoadjuvant CRT was safe and feasible, with no increase in surgical complications. Although complete response rates did not significantly improve, the dual ICI regimen demonstrated promising clinical activity. These findings support further translational research to optimize timing, dosing, and fractionation of radiotherapy and ICI therapy and to guide patient selection.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT04124601<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2025.27769","type":"journal-article","created":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T15:30:29Z","timestamp":1755876629000},"page":"e2527769","source":"Crossref","is-referenced-by-count":16,"title":["Dual Immune Checkpoint Inhibition Plus Neoadjuvant Chemoradiotherapy in Rectal Cancer"],"prefix":"10.1001","volume":"8","author":[{"given":"Johannes","family":"Laengle","sequence":"first","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Kuehrer","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Askin","family":"Kulu","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julijan","family":"Kabiljo","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daphni","family":"Ammon","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Zirnbauer","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Stift","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Herbst","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hospital of St John of God, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Dauser","sequence":"additional","affiliation":[{"name":"Department of Surgery, Hospital of St John of God, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Monschein","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinic Floridsdorf, Vienna Hospital Association, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Razek","sequence":"additional","affiliation":[{"name":"Department of Surgery, Clinic Floridsdorf, Vienna Hospital Association, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefanie","family":"Haegele","sequence":"additional","affiliation":[{"name":"Department of Pathology, Clinic Floridsdorf, Vienna Hospital Association, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Biebl","sequence":"additional","affiliation":[{"name":"Department of General and Visceral Surgery, Ordensklinikum Linz, Barmherzige Schwestern, Linz, Austria"},{"name":"Faculty of Medicine, Johannes Kepler University Linz, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Geinitz","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Johannes Kepler University Linz, Linz, Austria"},{"name":"Department of Radiation Oncology, Ordensklinikum Linz, Barmherzige Schwestern, Linz, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hulla","sequence":"additional","affiliation":[{"name":"Institute of Pathology, State Hospital Wiener Neustadt, Neustadt, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polina","family":"Kalinina","sequence":"additional","affiliation":[{"name":"Department of Pathology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonhard","family":"M\u00fcllauer","sequence":"additional","affiliation":[{"name":"Department of Pathology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Widder","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Bittermann","sequence":"additional","affiliation":[{"name":"Clinical Department of General, Visceral and Vascular Surgery, University Hospital Wiener Neustadt, Neustadt, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pils","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Tamandl","sequence":"additional","affiliation":[{"name":"Department of Biomedical Imaging and Image-guided Therapy, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Laengle","sequence":"additional","affiliation":[{"name":"Clinical Department of General, Visceral and Vascular Surgery, University Hospital Wiener Neustadt, Neustadt, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Schmid","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Division of Visceral Surgery, Department of General Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2025,8,22]]},"reference":[{"issue":"8","key":"zoi250786r1","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets.","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"zoi250786r2","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies.","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"issue":"26","key":"zoi250786r3","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency.","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"10135","key":"zoi250786r4","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1016\/S0140-6736(18)30789-X","article-title":"International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study.","volume":"391","author":"Pag\u00e8s","year":"2018","journal-title":"Lancet"},{"issue":"6349","key":"zoi250786r5","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"9","key":"zoi250786r6","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"459","key":"zoi250786r7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aat7807","article-title":"The hallmarks of successful anticancer immunotherapy.","volume":"10","author":"Galluzzi","year":"2018","journal-title":"Sci Transl Med"},{"issue":"pt 2","key":"zoi250786r8","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/j.semcancer.2022.05.015","article-title":"Neoadjuvant immunotherapy in gastrointestinal cancers\u2014the new standard of care?","volume":"86","author":"Petricevic","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"2","key":"zoi250786r9","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000667","article-title":"Short-course radiotherapy promotes pro-inflammatory macrophages via extracellular vesicles in human rectal cancer.","volume":"8","author":"Stary","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"8","key":"zoi250786r10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41571-018-0046-7","article-title":"Safety of combining radiotherapy with immune-checkpoint inhibition.","volume":"15","author":"Hwang","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"zoi250786r11","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.trecan.2016.05.002","article-title":"Radiotherapy: changing the game in immunotherapy.","volume":"2","author":"Demaria","year":"2016","journal-title":"Trends Cancer"},{"issue":"2","key":"zoi250786r12","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","article-title":"Irradiation and anti\u2013PD-L1 treatment synergistically promote antitumor immunity in mice.","volume":"124","author":"Deng","year":"2014","journal-title":"J Clin Invest"},{"key":"zoi250786r13","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejca.2016.06.015","article-title":"PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis.","volume":"65","author":"Hecht","year":"2016","journal-title":"Eur J Cancer"},{"issue":"4","key":"zoi250786r14","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1158\/2326-6066.CIR-14-0196","article-title":"Stereotactic radiation therapy augments antigen-specific PD-1\u2013mediated antitumor immune responses via cross-presentation of tumor antigen.","volume":"3","author":"Sharabi","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"zoi250786r15","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma.","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"34","key":"zoi250786r16","doi-asserted-by":"publisher","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study.","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"21","key":"zoi250786r17","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer.","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi250786r18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1038\/s41591-018-0337-7","article-title":"Neoadjuvant anti\u2013PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma.","volume":"25","author":"Cloughesy","year":"2019","journal-title":"Nat Med"},{"issue":"3","key":"zoi250786r19","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma.","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"issue":"21","key":"zoi250786r20","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer.","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi250786r21","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers.","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"issue":"6","key":"zoi250786r22","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S1470-2045(21)00149-2","article-title":"Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non\u2013small-cell lung cancer: a single-centre, randomised phase 2 trial.","volume":"22","author":"Altorki","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi250786r23","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S2468-1253(21)00427-1","article-title":"Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.","volume":"7","author":"Kaseb","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"zoi250786r24","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1038\/s41591-020-1086-y","article-title":"Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.","volume":"26","author":"Gao","year":"2020","journal-title":"Nat Med"},{"issue":"28","key":"zoi250786r25","doi-asserted-by":"publisher","first-page":"3308","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH).","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi250786r26","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.annonc.2024.06.015","article-title":"Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy in locally advanced rectal cancer (UNION): early outcomes of a multicenter randomized phase III trial.","volume":"35","author":"Lin","year":"2024","journal-title":"Ann Oncol"},{"issue":"9","key":"zoi250786r27","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1016\/j.ccell.2024.07.004","article-title":"Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: a randomized clinical trial.","volume":"42","author":"Xiao","year":"2024","journal-title":"Cancer Cell"},{"issue":"14","key":"zoi250786r28","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma.","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"22","key":"zoi250786r29","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden.","volume":"378","author":"Hellmann","year":"2018","journal-title":"N Engl J Med"},{"issue":"28","key":"zoi250786r30","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1200\/JCO.2017.76.6212","article-title":"CheckMate-032 Study: efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer.","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol"},{"issue":"9","key":"zoi250786r31","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti\u2013CTLA-4 therapy against melanoma.","volume":"210","author":"Simpson","year":"2013","journal-title":"J Exp Med"},{"issue":"4","key":"zoi250786r32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.ccell.2018.02.010","article-title":"Fc effector function contributes to the activity of human anti\u2013CTLA-4 antibodies.","volume":"33","author":"Arce Vargas","year":"2018","journal-title":"Cancer Cell"},{"issue":"9","key":"zoi250786r33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti\u2013PD-1 resistance.","volume":"20","author":"Verma","year":"2019","journal-title":"Nat Immunol"},{"issue":"6","key":"zoi250786r34","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"36","key":"zoi250786r35","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi250786r36","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy.","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"key":"zoi250786r37","first-page":"A51","article-title":"P08.04 Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial.","volume":"8","author":"Laengle","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"15","key":"zoi250786r38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS3623","article-title":"Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial.","volume":"39","author":"Laengle","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"zoi250786r39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e15604","article-title":"Interim analysis of neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): a prospective randomized, open-label, multicenter, phase II clinical trial.","volume":"40","author":"Laengle","year":"2022","journal-title":"J Clin Oncol"},{"key":"zoi250786r40","doi-asserted-by":"publisher","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"issue":"20","key":"zoi250786r41","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"1","key":"zoi250786r42","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s003840050072","article-title":"Pathological features of rectal cancer after preoperative radiochemotherapy.","volume":"12","author":"Dworak","year":"1997","journal-title":"Int J Colorectal Dis"},{"issue":"28","key":"zoi250786r43","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1200\/JCO.2011.34.9068","article-title":"Magnetic resonance imaging\u2013detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience.","volume":"29","author":"Patel","year":"2011","journal-title":"J Clin Oncol"},{"issue":"5","key":"zoi250786r44","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11888-015-0285-2","article-title":"Neoadjuvant Rectal (NAR) score: a new surrogate endpoint in rectal cancer clinical trials.","volume":"11","author":"George","year":"2015","journal-title":"Curr Colorectal Cancer Rep"},{"issue":"7","key":"zoi250786r45","doi-asserted-by":"publisher","first-page":"e314","DOI":"10.1016\/S1470-2045(21)00053-X","article-title":"The concept and use of the neoadjuvant rectal score as a composite endpoint in rectal cancer.","volume":"22","author":"Glynne-Jones","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi250786r46","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/S1470-2045(17)30086-4","article-title":"Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial.","volume":"18","author":"Erlandsson","year":"2017","journal-title":"Lancet Oncol"},{"issue":"3","key":"zoi250786r48","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/ijc.32132","article-title":"A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors.","volume":"145","author":"Arnaud-Coffin","year":"2019","journal-title":"Int J Cancer"},{"issue":"2","key":"zoi250786r49","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.clon.2007.11.013","article-title":"Chemoradiotherapy for rectal cancer: an updated analysis of factors affecting pathological response.","volume":"20","author":"Sanghera","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"4","key":"zoi250786r50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/01.sla.0000141194.27992.32","article-title":"Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results.","volume":"240","author":"Habr-Gama","year":"2004","journal-title":"Ann Surg"},{"issue":"4","key":"zoi250786r51","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.ijrobp.2013.12.012","article-title":"Local recurrence after complete clinical response and watch and wait in rectal cancer after neoadjuvant chemoradiation: impact of salvage therapy on local disease control.","volume":"88","author":"Habr-Gama","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"zoi250786r52","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"issue":"1","key":"zoi250786r53","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial.","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"issue":"15","key":"zoi250786r54","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1200\/JCO.21.01667","article-title":"Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR).","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi250786r55","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.1097\/SLA.0000000000005799","article-title":"Locoregional failure during and after short-course radiotherapy followed by chemotherapy and surgery compared to long-course chemoradiotherapy and surgery\u2014a five-year follow-up of the RAPIDO trial.","volume":"278","author":"Dijkstra","year":"2023","journal-title":"Ann Surg"},{"issue":"12","key":"zoi250786r56","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1038\/s41571-021-00538-5","article-title":"International consensus recommendations on key outcome measures for organ preservation after (chemo)radiotherapy in patients with rectal cancer.","volume":"18","author":"Fokas","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"zoi250786r57","doi-asserted-by":"publisher","first-page":"S1170","DOI":"10.1016\/S0167-8140(25)00493-1","article-title":"S1171 Clinical Lower GI ESTRO. 489 STAR-TREC (NCT02945566): a randomised phase II\/III trial of CRT versus 5 \u00d7 5 Gy SCRT for organ preservation in early\/intermediate risk rectal cancer.","volume":"205","author":"Marijnen","year":"2025","journal-title":"Radiother Oncol"},{"issue":"4","key":"zoi250786r58","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2468-1253(22)00392-2","article-title":"Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2-cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial.","volume":"8","author":"Gerard","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"zoi250786r59","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial.","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"issue":"6","key":"zoi250786r60","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/1078-0432.CCR-21-3213","article-title":"Preoperative chemoradiotherapy plus nivolumab before surgery in patients with microsatellite stable and microsatellite instability\u2013high locally advanced rectal cancer.","volume":"28","author":"Bando","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"11","key":"zoi250786r61","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003554","article-title":"Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer.","volume":"9","author":"Lin","year":"2021","journal-title":"J Immunother Cancer"},{"key":"zoi250786r47","unstructured":"R Core Team. R: A language and environment for statistical computing. 2023. https:\/\/www.r-project.org\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2837936\/laengle_2025_oi_250786_1790695714.28498.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:00:51Z","timestamp":1791212451000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2837936"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,8,22]]},"references-count":61,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27769","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,22]]}}}